-
ALSO READ
Zydus Cadila gets USFDA's final approval to market antidepressant drug Cadila Healthcare gains 4% on USFDA nod for Metoprolol Succinate tablets Zydus Cadila gets USFDA nod to market treatment for gout, excess uric acid Zydus Cadila gets USFDA approval for anti-depression drug Zydus Cadila gets USFDA nod to sell erectile dysfunction drug Tadalafil -
Drug firm Zydus Cadila on Monday said it has received the final nod from US health regulator to market Metoprolol Succinate extended-release tablets, used for treatment of various cardiac conditions, in the American market.
The product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said in a statement.
The company has received "final approval from the United States Food and Drug Administration (USFDA) to market Metoprolol Succinate extended-release tablets USP in the strengths of 25 mg, 50 mg, 100 mg and 200 mg", it said.
"The drug is used to treat chest pain (angina), heart failure and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems," it said.
The group now has more than 185 approvals and has so far filed over 320 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Cadila Healthcare stock was trading 4.27 per cent up at Rs 385.75 in the afternoon on BSE.
RECOMMENDED FOR YOU